(Wired) – The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes.

The US Food and Drug Administration has determined that semaglutide is no longer in shortage, a move that will have implications for patients taking cheaper, compounded versions of the drug. (Read More)